A method of inhibiting 15-keto prostaglandin-Δ
13
-reductase 2 by contacting 15-keto prostaglandin-Δ
13
-reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also disclosed are methods of treating peroxisome proliferators-activated receptor related diseases and lowering blood glucose levels by administering to a subject in need thereof an effective amount of such an aryl compound.
Sulfoxide-mediated approach to flavones through one-pot Knoevenagel condensation/oxa-Michael addition/sulfoxide elimination process of β-(o-hydroxyaryl)-ketosulfone with arylaldehydes
gram-scale synthesis of flavones is described by a one-pot straightforward sulfoxide-mediated Knoevenagel condensation/intermolecular oxa-Michael annulation/sulfoxide elimination process of β-(o-hydroxyaryl)-ketosulfones (dual nucleophile) and arylaldehydes (dual electrophile). The expeditious synthetic route sets up flavones, including the bond formation of one CO and one double CC bonds via a formal (5 + 1)
在本文中,通过一锅法直接亚砜介导的 Knoevenagel 缩合/分子间 oxa-Michael 环化/β-(o-羟基芳基)-酮砜(双亲核试剂)和芳基醛(双亲电试剂)。快速合成路线建立了黄酮,包括通过形式 (5 + 1) 环加成形成一个 C O 键和一个双 C C 键。此外,其中,化合物70 亿可能是进一步开发药物以造福抗衰老领域的绝佳起点。
[EN] PROSTAGLANDIN REDUCTASE INHIBITORS<br/>[FR] INHIBITEURS DE PROSTAGLANDINE RÉDUCTASES
申请人:ABGENOMICS CORP
公开号:WO2007082178A2
公开(公告)日:2007-07-19
[EN] A method of inhibiting 15-keto prostaglandin-?13-reductase 2 by contacting 15-keto prostaglandin-?13-reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also disclosed are methods of treating peroxisome proliferators-activated receptor related diseases and lowering blood glucose levels by administering to a subject in need thereof an effective amount of such an aryl compound. [FR] Procédé d'inhibition de la 15-céto-prostaglandine-?13-réductase 2 par la mise en contact de la 15-céto-prostaglandine-?13-réductase 2 avec un composé aryle de formule (I), (II), (III) ou (IV) illustrée dans la présente invention. La présente invention concerne également des procédés de traitement de maladies liées au récepteur activé par des proliférateurs de peroxysome et d'abaissement des taux de glucose sanguin en administrant une quantité efficace de ce composé d'aryle à un sujet nécessitant un tel traitement.